Hormone replacement therapy will no longer carry a warning label, FDA says

On November 10, 2025, the FDA declared that hormone replacement therapy (HRT) for menopause will no longer include a black box warning about serious health risks, including breast cancer, heart attack, and stroke. This change is expected to have a positive impact on women's health choices, potentially increasing the acceptance and use of HRT among those experiencing menopause. The removal of such warnings may alleviate concerns that have historically deterred women from seeking these treatments, thus promoting better management of menopausal symptoms. The FDA's decision reflects a growing understanding of the benefits of HRT, which can significantly improve quality of life for many women. As discussions around women's health continue to evolve, this announcement marks a pivotal moment in the approach to menopause treatment, encouraging a more informed and less fearful dialogue about hormone therapies.